Consistent with CTLA-4 and PD-1 blockade, the effects of feladilimab on T-cell activation are anticipated to modulate T-cell dynamics, promote immune-mediated tumor regression, and improve survival of patients whose tumors have intrinsically activated T cells or whose immune systems are primed, either by prior treatments or rational combination of therapies that promote immune priming, such as anti-CTLA-4 or anti-PD-1 mAbs, chemotherapy, or radiotherapy (2, 20–23). This evidence concerns the gene PDCD1 and neoplasm.